217 related articles for article (PubMed ID: 34439135)
1. Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia.
Ikeda S; Kato T; Kenmotsu H; Sekine A; Baba T; Ogura T
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439135
[TBL] [Abstract][Full Text] [Related]
2. Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis.
Otoshi R; Ikeda S; Kaneko T; Sagawa S; Yamada C; Kumagai K; Moriuchi A; Sekine A; Baba T; Ogura T
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730686
[TBL] [Abstract][Full Text] [Related]
3.
Fujimoto K; Ikeda S; Tabata E; Kaneko T; Sagawa S; Yamada C; Kumagai K; Fukushima T; Haga S; Watanabe M; Muraoka T; Sekine A; Baba T; Ogura T
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611005
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Iwasawa S; Iwasawa T; Kasajima R; Miyagi Y; Misumi T; Yamanaka T; Okamoto H
Ther Adv Med Oncol; 2020; 12():1758835920922022. PubMed ID: 32426051
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Iwasawa S; Sato Y; Harada T; Kubota K; Tokito T; Okamoto I; Furuya N; Yokoyama T; Hosokawa S; Iwasawa T; Yamanaka T; Okamoto H
J Thorac Oncol; 2020 Dec; 15(12):1935-1942. PubMed ID: 32858235
[TBL] [Abstract][Full Text] [Related]
7. Managing Lung Cancer with Comorbid Interstitial Pneumonia.
Ichihara E; Miyahara N; Maeda Y; Kiura K
Intern Med; 2020 Jan; 59(2):163-167. PubMed ID: 31534086
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Sato Y; Hino A; Harada T; Kubota K; Tokito T; Okamoto I; Furuya N; Yokoyama T; Hosokawa S; Iwasawa T; Kasajima R; Miyagi Y; Misumi T; Okamoto H
Oncologist; 2022 Sep; 27(9):720-e702. PubMed ID: 35759340
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.
Yamaguchi T; Shimizu J; Oya Y; Watanabe N; Hasegawa T; Horio Y; Inaba Y; Fujiwara Y
Thorac Cancer; 2022 Mar; 13(5):724-731. PubMed ID: 35044093
[TBL] [Abstract][Full Text] [Related]
10. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in surgically managed non-small-cell lung cancer patients with evidence of interstitial pneumonia identified on preoperative radiology or incidentally on postoperative histology.
Maniwa T; Kondo H; Mori K; Sato T; Teramukai S; Ebina M; Kishi K; Watanabe A; Sugiyama Y; Date H
Interact Cardiovasc Thorac Surg; 2015 May; 20(5):641-6. PubMed ID: 25712985
[TBL] [Abstract][Full Text] [Related]
13. Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study.
Araya T; Kita T; Ueda T; Terada N; Sakai T; Yamamura K; Kurokawa K; Uchida Y; Sone T; Kimura H; Kasahara K
Can Respir J; 2019; 2019():5315903. PubMed ID: 31015884
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer.
Kashiwada T; Saito Y; Terasaki Y; Hisakane K; Takeuchi S; Sugano T; Miyanaga A; Noro R; Minegishi Y; Seike M; Kubota K; Gemma A
Jpn J Clin Oncol; 2019 Feb; 49(2):165-173. PubMed ID: 30508192
[TBL] [Abstract][Full Text] [Related]
15. Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
Fukuizumi A; Minegishi Y; Omori M; Atsumi K; Takano N; Hisakane K; Takahashi S; Kobayashi K; Sugano T; Takeuchi S; Noro R; Seike M; Kubota K; Azuma A; Gemma A
Int J Clin Oncol; 2019 Dec; 24(12):1543-1548. PubMed ID: 31352631
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of non-small-cell lung cancer with interstitial pneumonia: variation in cancer location, histopathology, and frequency of postoperative acute exacerbations in interstitial pneumonia.
Ogawa K; Uruga H; Fujii T; Fujimori S; Kohno T; Kurosaki A; Kishi K; Abe S
BMC Pulm Med; 2020 Nov; 20(1):307. PubMed ID: 33218332
[TBL] [Abstract][Full Text] [Related]
17. Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study.
Ichimura T; Hinata M; Ichikura D; Suzuki S
Cancer Chemother Pharmacol; 2022 Jan; 89(1):21-30. PubMed ID: 34648059
[TBL] [Abstract][Full Text] [Related]
18. Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies.
Matsumoto K; Shiroyama T; Kuge T; Miyake K; Yamamoto Y; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
Transl Lung Cancer Res; 2022 Sep; 11(9):1835-1846. PubMed ID: 36248332
[TBL] [Abstract][Full Text] [Related]
19. [Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis].
Kolek V; Vašáková M; Šterclová M; Cwiertka K; Vrána D; Kudláček A; Skřičková J; Pešek M; Petera J
Klin Onkol; 2017; 30(4):303-306. PubMed ID: 28832178
[TBL] [Abstract][Full Text] [Related]
20. Perioperative management of hepatectomy in patients with interstitial pneumonia: a report of three cases and a literature review.
Kubo N; Araki K; Yamanaka T; Hoshino K; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Hirai K; Saitoh F; Kuwano H; Shirabe K
Surg Today; 2017 Oct; 47(10):1173-1179. PubMed ID: 28251374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
